Coronary Artery Disease and Myocardial Infarction

View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease

Isla Mackenzie,

Watch time: 2m 29s
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Watch time: 7m 9s

Tracey M Ellimuttil , Kimberly Harrison , Allman T Rollins , et al

ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

Watch time: 9m 1s

Ivan Milinkovic , Giuseppe Rosano , Yury Lopatin , et al

John Pepper ,

AHA 2019: Empagliflozin on Erythropoietin Levels

David Mazer,

Watch time: 3m 56s
ESC 2019 - Results of the Phase 3 ORION-11 trial

Kausik Ray,

Watch time: 4m 57s
ESC 2018: CAMELLIA-TIMI 61

Erin A Bohula,

Watch time: 3m 42s

Ivan Milinkovic , Giuseppe Rosano , Yury Lopatin , et al

John Pepper ,

Thumbnail

Ulf Landmesser,

Watch time: 4m 32s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s

Tracey M Ellimuttil , Kimberly Harrison , Allman T Rollins , et al

4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Watch time: 7m 9s
HFA 2018 by Dr Kelley Branch

Kelley Branch,

Watch time: 5m 18s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease

Isla Mackenzie,

Watch time: 2m 29s
ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

Watch time: 9m 1s
ESC 2018: CAMELLIA-TIMI 61

Erin A Bohula,

Watch time: 3m 42s

Colin Berry,

Watch time: 29s

Media

View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease

Isla Mackenzie,

Watch time: 2m 29s
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Watch time: 7m 9s
ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

Watch time: 9m 1s
AHA 2019: Empagliflozin on Erythropoietin Levels

David Mazer,

Watch time: 3m 56s
ESC 2019 - Results of the Phase 3 ORION-11 trial

Kausik Ray,

Watch time: 4m 57s
ESC 2018: CAMELLIA-TIMI 61

Erin A Bohula,

Watch time: 3m 42s
HFA 2018 by Dr Kelley Branch

Kelley Branch,

Watch time: 5m 18s

Ajay J Kirtane,

Watch time: 24s

Ajay J Kirtane,

Watch time: 29s

Colin Berry,

Watch time: 29s
Thumbnail

Ulf Landmesser,

Watch time: 4m 32s

Articles

Statin Intensity and Cardiac Allograft Vasculopathy

Tracey M Ellimuttil

,

Kimberly Harrison

,

Allman T Rollins

,

Irene D Feurer

,

Scott A Rega

,

Jennifer Gray

,

Jonathan Menachem

,

Published:

12 November 2021

Citation:

Cardiac Failure Review 2021;7:e15.

DOI:

https://doi.org/10.15420/cfr.2021.07
  • Views: Views 689
  • Downloads: Downloads 22

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines

Ivan Milinkovic

,

Giuseppe Rosano

,

Yury Lopatin

,

Petar M Seferovic

,

Citation:

Cardiac Failure Review, 2016;2(2):123–9

DOI:

https://doi.org/10.15420/cfr.2016:13:1
  • Views: Views 5258
  • Downloads: Downloads 12
  • Citations: 5

Managing Heart Failure Patients with Multivessel Disease

John Pepper

,

Citation:

Cardiac Failure Review 2015;1(2):118–22

DOI:

https://doi.org/10.15420/cfr.2015.1.2.118
  • Views: Views 1989
  • Downloads: Downloads 9
  • Citations: 3